[Interdisciplinary strategies for the prevention and treatment of MASLD].

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) is one of the most common causes of liver cirrhosis and hepatocellular carcinoma. The severity of the metabolic syndrome and in particular type 2 diabetes are major risk factors for the progression of liver disease, but also for the frequent occurrence of cardiovascular complications. Patients therefore benefit in particular from an interdisciplinary treatment. This article provides an overview of recommended strategies for the prevention and treatment of MASLD.